Core Viewpoint - Shenzhen Kaili Biomedical Technology Co., Ltd. is implementing a stock incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and employees for long-term development [1][2]. Summary by Sections 1. Purpose of Assessment - The assessment aims to establish a long-term incentive mechanism to attract and retain talent, enhancing employee motivation and creativity while aligning the interests of shareholders, the company, and employees [1]. 2. Principles of Assessment - The assessment must adhere to principles of fairness, openness, and impartiality, closely linking the stock incentive plan with the performance and contributions of the incentivized individuals to maximize the interests of the company and all shareholders [2]. 3. Assessment Targets - The assessment applies to all participants in the stock incentive plan, including certain directors, senior management, middle management, and key technical personnel, excluding independent directors, supervisors, foreign employees, and shareholders holding more than 5% of the company's shares [2]. 4. Assessment Organization - The Board of Directors' Compensation and Assessment Committee is responsible for organizing and reviewing the assessment, while a working group composed of the Board Office, Human Resources Department, and Finance Department will implement the assessment [2]. 5. Assessment Indicators and Standards - The performance assessment for the stock incentive plan spans from 2025 to 2028, with specific net profit growth targets set for each year based on the 2024 net profit of 136.49 million yuan, requiring growth rates of at least 30% in 2025, 70% in 2026, 150% in 2027, and 260% in 2028 [3]. 6. Implementation of the Plan - If the company fails to meet the performance targets in any assessment year, the corresponding restricted stocks and stock options for that year will not vest or be exercised, and will be rendered void [3][4]. 7. Assessment Period and Frequency - The assessment period for the stock incentive plan is set for four accounting years from 2025 to 2028, with assessments conducted annually [4]. 8. Assessment Procedure - The assessment working group collects relevant business and financial data, evaluates whether the company and individuals meet the performance targets, and submits a performance assessment report to the Compensation and Assessment Committee [4][5]. 9. Management of Assessment Results - Assessment results will be communicated to the assessed individuals within seven working days, allowing for appeals, which must be reviewed within five working days [5].

Core Viewpoint - The company has repurchased a total of 19.5039 million shares, representing approximately 0.79% of its total share capital, with a total transaction amount of RMB 251 million, excluding transaction fees [1] Group 1 - The share repurchase is in line with the company's established plan and relevant laws and regulations [1] - The repurchased shares are intended for employee stock ownership plans or equity incentives to enhance long-term incentive mechanisms [1] - The initiative aims to strengthen team cohesion and competitiveness, promoting the company's long-term development [1]

Core Viewpoint - The incentive plan of Xiamen Tebao Biological Engineering Co., Ltd. involves the allocation of restricted stocks to 372 individuals, with a total of 1.2 million shares reserved for distribution, representing 0.29% of the total share capital at the time of the plan's submission to the shareholders' meeting [1] Group 1 - The total number of restricted stocks granted to the incentive recipients is 1.2 million shares [1] - The reserved shares account for 100% of the total reserved grant of restricted stocks [1] - The total number of shares involved in the incentive plan does not exceed 1% of the company's total share capital at the time of the plan's submission [1]

Core Viewpoint - The announcement details the results of the stock incentive plan for the first category of incentive objects' fourth vesting period and the second category's third vesting period, highlighting the failure of certain stocks to vest due to performance targets not being met and the departure of some incentive objects [1][8][9]. Group 1: Stock Incentive Plan Overview - The stock incentive plan was approved during the board meeting on May 28, 2020, and subsequently ratified by the shareholders on June 19, 2020 [1][3]. - The plan included a public notice period from June 1 to June 11, 2020, during which no objections were raised regarding the incentive objects [2]. Group 2: Vesting Results - For the first category of incentive objects, 38.825 thousand shares failed to vest due to 11 individuals leaving the company and the company's failure to meet the performance targets for the fourth vesting period [7][8]. - For the second category of incentive objects, 14.6025 thousand shares failed to vest due to one individual leaving and not meeting the performance targets for the third vesting period [8][9]. Group 3: Impact of Non-Vesting - The non-vesting of these shares is not expected to materially impact the company's financial status or operational results, nor will it affect the stability of the core management team [9].

Core Viewpoint - The legal opinion letter confirms that Nanjing Julong Technology Co., Ltd. has obtained the necessary approvals and authorizations for the adjustment and initial grant of the 2025 second phase restricted stock incentive plan, in compliance with relevant laws and regulations [4][11]. Summary by Sections Approval and Authorization - The company has completed the necessary procedures for the adjustment and initial grant of the incentive plan, including meetings of the compensation and assessment committee, board of directors, and supervisory board, all of which approved relevant proposals [4][5][6]. Adjustment of Grant Price - The grant price of the restricted stock was adjusted from 13.21 to 12.96 yuan per share due to a cash dividend distribution of 2.5 yuan per 10 shares, which was approved at the 2024 annual general meeting [7][8]. Grant Conditions - The initial grant conditions have been met, with no disqualifying events occurring for the incentive objects, such as negative audit opinions or regulatory penalties [9][11]. Grant Details - The initial grant date is set for September 5, 2025, with a grant price of 12.96 yuan per share for 635,000 shares to 10 incentive objects, as authorized by the board of directors [10][11].

证券代码：688278 证券简称：特宝生物 公告编号：2025- 厦门特宝生物工程股份有限公司 关于向 2024 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ? 限 制 性 股 票 预 留 授 予 数 量 ： 120.00 万 股 ， 占 目 前 公 司 股 本 总 额 重要内容提示： ? 股权激励方式：第二类限制性股票 ? 限制性股票预留授予日：2025 年 9 月 4 日 厦门特宝生物工程股份有限公司（以下简称"公司"）《2024 年限制性股 票激励计划（草案）》（以下简称"《激励计划（草案）》"或"本激励计划"） 规定的限制性股票授予条件已经成就，根据公司 2024 年第一次临时股东大会的 授权，公司于 2025 年 9 月 4 日分别召开第九届董事会第十一次会议和第九届监 事会第八次会议，审议通过了《关于向 2024 年限制性股票激励计划激励对象授 予预留部分限制性股票的议案》，确定 2025 年 9 月 4 日为预留授予日，以 39.18 元/股的授 ...

Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and the list of initial grant recipients, ensuring compliance with relevant laws and regulations [1][2][3] Group 1: Announcement Details - The company held meetings on August 25, 2025, to review and approve the 2025 Restricted Stock Incentive Plan and its management measures [1] - The details of the plan and the list of initial grant recipients were publicly disclosed on August 26, 2025, on the official information platform [2] Group 2: Verification Process - The company conducted an internal verification of the initial grant recipient list, including checks on identification documents and employment contracts [2][3] - The verification confirmed that all listed recipients meet the eligibility criteria set forth in the relevant regulations [3] Group 3: Recipient Eligibility - The initial grant recipient list does not include independent directors, major shareholders, or their immediate family members [4] - The plan includes foreign employees in key positions, which is deemed necessary for attracting and retaining high-end talent [4]

Core Viewpoint - Hua Bao International (00336) saw a significant increase in stock price, rising over 4% in early trading, attributed to the announcement of a stock option plan aimed at boosting confidence and expanding overseas market efforts [1] Group 1: Stock Performance - The stock price of Hua Bao International increased by 5.43%, reaching HKD 4.27, with a trading volume of HKD 15.6985 million [1] Group 2: Company Announcement - The company announced a stock option plan for 148 million options to eligible participants, with performance targets set for revenue growth of at least 10%/20%/30% for the years 2026/2027/2028 compared to 2025 [1] Group 3: Financial Performance - In the first half of the year, Hua Bao International reported revenue of CNY 1.621 billion, a year-on-year increase of 2.5% - The net profit attributable to shareholders was CNY 118 million, reflecting a year-on-year increase of 298% - Adjusted net profit for the period was CNY 192 million, showing a year-on-year growth of 2.1% [1] Group 4: Future Outlook - According to a report from Zheshang Securities, the company's operations are stabilizing, with significant growth in tobacco raw materials, positioning it as a core target in the upstream supply chain of HNB [1] - The company plans to accelerate international development and enhance overseas market expansion, focusing on supply chain management and growth through mergers and acquisitions [1] - As of the first half of 2025, the company had cash and trading financial assets totaling CNY 6 billion [1]

Core Viewpoint - Beijing Lier's share buyback has boosted investor confidence, with a significant increase in stock price during the buyback period [1][2][3]. Buyback Details - The buyback program initiated on September 30, 2024, involved repurchasing 25.21 million shares, representing 2.12% of the total share capital, at a total cost of 104 million yuan (excluding transaction fees) [2]. - The buyback was funded through self-raised funds and a loan of up to 120 million yuan from China Everbright Bank [2]. - The stock price increased from 3.42 yuan per share to 8.34 yuan per share during the buyback period, reflecting a rise of approximately 144% [1][3]. Financial Performance - In the first half of 2025, Beijing Lier reported revenue of 3.457 billion yuan, an increase of 8.22% year-on-year, and a net profit of 218 million yuan, a slight increase of 0.18% [1][4]. - The company's revenue grew from 4.719 billion yuan in 2022 to 6.327 billion yuan in 2024, although net profit fluctuated significantly during the same period [4]. R&D Investment - The company has increased its R&D expenditure, investing 242 million yuan in the first half of 2025, a year-on-year increase of 41.67% [6]. - As of June 30, 2025, Beijing Lier held 830 authorized patents, including 237 invention patents, and has made significant contributions to various national and provincial standards [6]. Future Outlook - Beijing Lier remains optimistic about achieving growth in both revenue and profit for the full year, supported by new production lines and positive trends in overseas business [6].

Group 1 - The core decision of the meeting was to adjust the reserved grant price for the 2025 restricted stock incentive plan to be consistent with the initial grant price of 4.60 CNY per share [1][2] - The company distributed cash dividends of 0.5 CNY (including tax) for every 10 shares based on a total share capital of 784,164,678 shares as of the record date of May 29, 2025 [1] - Following the dividend distribution, the adjusted grant price for the reserved restricted stock is set at 4.55 CNY per share after accounting for the dividend [2][3] Group 2 - The board approved the grant of a total of 1 million shares of restricted stock to 8 eligible incentive recipients, with the grant date set for September 4, 2025 [2][3] - The remuneration and assessment committee confirmed that the adjustments comply with relevant regulations and will not materially affect the company's financial status or operational results [2][4] - The voting results for the proposals were unanimous, with 3 votes in favor and no opposition or abstentions [2][4]